About: Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.61 (-7.76%)
AUTL NASDAQ Autolus Therapeutics Ltd
Autolus Therapeutics Ltd share price
AUTL price activity
Last Price
$1.610
Change (24hr)
-0.14 USD (-7.76%)
Volume
1.83M
Volume (4w avg)
-
Open
$1.74
Day Range
$1.61 - $1.74
Previous Close
$1.74
Last Trade
13 Oct, 7:07 pm GMT+0
Delayed
13 Oct, 7:07 pm GMT+0
AUTL price performance
Delayed
13 Oct, 7:07 pm GMT+0
AUTL Market Signals